How do you decide between Nivolumab + Ipilimumab and Pembrolizumab or Nivolumab monotherapy in later lines of MSI-H Colorectal cancer?  

The data are fairly clear that patients with the combination of nivolumab and ipilimumab is highly active based on the Checkmate-142 study (Overman, et al, JCO 36, no. 8 (March 10 2018): 773-779, 2018) showing a 55% RR with 5% CR (n=119 patients, all post at least 2 prior chemo regimens). ...